Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls

Srdan Verstovsek, Hagop M. Kantarjian, Zeev Estrov, Jorge E. Cortes, Deborah A. Thomas, Tapan Kadia, Sherry Pierce, Elias Jabbour, Gautham Borthakur, Elisa Rumi, Ester Pungolino, Enrica Morra, Domenica Caramazza, Mario Cazzola, Francesco Passamonti

Research output: Contribution to journalArticlepeer-review

159 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds